ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada
ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada, which aims …
ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »
